Urinary tract cancer risk (7 studies) · adults (aged at least 18 years)
It is very uncertain whether highest changes urinary tract cancer risk (7 studies) compared with lowest green tea exposure (very low certainty).
1 finding from 1 review
RR 1.04 [0.79, 1.37]
156039 participants
Very low
Non‐melanoma skin cancer incidence · adults (aged at least 18 years)
Green tea extract supplementation showed no clear difference in non‐melanoma skin cancer incidence compared with placebo (low certainty).
1 finding from 1 review
Quality of life · adults (aged at least 18 years)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Incidence: all cancers · adults (aged at least 18 years)
Highest showed no clear difference in any cancer incidence (3 studies) compared with lowest green tea exposure (low certainty).
1 finding from 1 review
RR 0.83 [0.65, 1.07]
52479 participants
Low
Mortality: all cancers · adults (aged at least 18 years)
Highest showed no clear difference in any cancer mortality (8 studies) compared with lowest green tea exposure (low certainty).
1 finding from 1 review
RR 0.99 [0.91, 1.07]
504366 participants
Low
Oral cancer risk · adults (aged at least 18 years)
Highest may leads to lower oral cancer risk (5 studies) compared with lowest green tea exposure (low certainty).
1 finding from 1 review
RR 0.71
55977 participants
Low
Any gut cancer risk (7 studies) · adults (aged at least 18 years)
Highest showed no clear difference in any gut cancer risk (7 studies) compared with lowest green tea exposure (low certainty).
1 finding from 1 review
RR 0.78 [0.59, 1.02]
70299 participants
Low
Cognitive and neurobehavioural outcomes · children (aged 0–2 years)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · children (aged 0–6 years)
The review found no eligible studies for this question.
2 findings from 1 review
Blood lead levels (continuous)Blood lead level at end of duration Scale: 0–30 · children (aged 0–6 years)
2 findings from 1 review
Cognitive and neurobehavioural outcomes · children (aged 0–4 years)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · children (aged 0–4 years)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Blood lead levels (continuous)Blood lead level at end of duration Scale: 0–30 · children (aged 0–4 years)
1 finding from 1 review
Household dust: floor dust lead levels · children (aged 0–4 years)
1 finding from 1 review
Adverse events · children (aged 0–2 years)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Blood lead levels (continuous)Blood lead level at end of duration Scale: 0–30 · children (aged 0–2 years)
1 finding from 1 review
Floor dust ‐ hard floor (continuous) Floor dust lead levels Scale from: 0 to 40 · children (aged 0–2 years)
1 finding from 1 review
Cognitive and neurobehavioural outcomes · children (aged 0–6 years)
2 findings from 1 review
Household dust: floor dust lead levels · children (aged 0–6 years)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
50% or greater reduction in seizure frequency · people (aged 10–64 years) with drug‐resistant focal epilepsy
Vigabatrin may leads to higher ≥ 50% reduction in seizure frequency (ITT analysis) Duration of… compared with placebo (low certainty).
1 finding from 1 review